Agomab Therapeutics Nv Adr (AGMB)

Mar 03, 2026

AgomAb Therapeutics NV ADR Earnings and Revenue – DUS:M5E - TradingView

Mar 03, 2026

Mar 03, 2026

Basic earnings per share (basic EPS) of AgomAb Therapeutics NV ADR – DUS:M5E - TradingView

Mar 03, 2026

Mar 03, 2026

Free float of AgomAb Therapeutics NV ADR – DUS:M5E - TradingView

Mar 03, 2026

Mar 02, 2026

Total common shares outstanding of AgomAb Therapeutics NV ADR – TRADEGATE:M5E - TradingView

Mar 02, 2026

Mar 02, 2026

Debt to assets ratio of AgomAb Therapeutics NV ADR – TRADEGATE:M5E - TradingView

Mar 02, 2026

Mar 02, 2026

Net current asset value per share of AgomAb Therapeutics NV ADR – TRADEGATE:M5E - TradingView

Mar 02, 2026

Mar 02, 2026

Enterprise value to EBITDA ratio of AgomAb Therapeutics NV ADR – TRADEGATE:M5E - TradingView

Mar 02, 2026

Mar 02, 2026

EBITDA margin % of AgomAb Therapeutics NV ADR – TRADEGATE:M5E - TradingView

Mar 02, 2026

Mar 02, 2026

AgomAb Therapeutics NV ADR Cash Flow – TRADEGATE:M5E - TradingView

Mar 02, 2026

Mar 02, 2026

AgomAb Therapeutics NV ADR Balance Sheet – TRADEGATE:M5E - TradingView

Mar 02, 2026

Mar 02, 2026

EBITDA of AgomAb Therapeutics NV ADR – TRADEGATE:M5E - TradingView

Mar 02, 2026

Mar 02, 2026

Diluted earnings per share (diluted EPS) of AgomAb Therapeutics NV ADR – TRADEGATE:M5E - TradingView

Mar 02, 2026

Mar 02, 2026

Non-operating income (total) of AgomAb Therapeutics NV ADR – TRADEGATE:M5E - TradingView

Mar 02, 2026

Mar 02, 2026

AgomAb Therapeutics NV ADR Financial Statements – TRADEGATE:M5E - TradingView

Mar 02, 2026

Mar 02, 2026

Diluted net income available to common stockholders of AgomAb Therapeutics NV ADR – TRADEGATE:M5E - TradingView

Mar 02, 2026

Mar 02, 2026

AgomAb Therapeutics NV ADR Revenue Breakdown – TRADEGATE:M5E - TradingView

Mar 02, 2026

Mar 02, 2026

AgomAb Therapeutics NV ADR Statistics – TRADEGATE:M5E - TradingView

Mar 02, 2026

Mar 02, 2026

Gross profit of AgomAb Therapeutics NV ADR – TRADEGATE:M5E - TradingView

Mar 02, 2026

Mar 02, 2026

Net income before discontinued operations of AgomAb Therapeutics NV ADR – TRADEGATE:M5E - TradingView

Mar 02, 2026

Mar 02, 2026

Operating income of AgomAb Therapeutics NV ADR – TRADEGATE:M5E - TradingView

Mar 02, 2026

Mar 02, 2026

Total revenue of AgomAb Therapeutics NV ADR – TRADEGATE:M5E - TradingView

Mar 02, 2026

Mar 02, 2026

Non-controlling/minority interest of AgomAb Therapeutics NV ADR – TRADEGATE:M5E - TradingView

Mar 02, 2026

Mar 02, 2026

AgomAb Therapeutics NV ADR Income Statement – TRADEGATE:M5E - TradingView

Mar 02, 2026

Mar 02, 2026

AgomAb Therapeutics NV ADR Earnings and Revenue – TRADEGATE:M5E - TradingView

Mar 02, 2026

Mar 02, 2026

Free float of AgomAb Therapeutics NV ADR – TRADEGATE:M5E - TradingView

Mar 02, 2026

Feb 10, 2026

Agomab closes $200 million IPO on NASDAQ - Investing.com India

Feb 10, 2026

Feb 09, 2026

Agomab closes $200 million IPO on NASDAQ By Investing.com - Investing.com Nigeria

Feb 09, 2026

Feb 09, 2026

Agomab Announces Closing of Initial Public Offering - Benzinga

Feb 09, 2026

Feb 08, 2026

EQT Life Sciences-Backed AgomAb Falls After $200 Million IPO - Mint

Feb 08, 2026

Feb 06, 2026

Agomab Therapeutics opens below IPO price in Nasdaq debut By Investing.com - Investing.com Canada

Feb 06, 2026

Feb 06, 2026

Agomab Therapeutics opens below IPO price in Nasdaq debut - Investing.com

Feb 06, 2026

Feb 05, 2026

Agomab prices IPO at $16 per share, aims to raise $200 million - Investing.com Australia

Feb 05, 2026

Feb 05, 2026

Agomab prices IPO at $16 per share, aims to raise $200 million By Investing.com - Investing.com India

Feb 05, 2026

Jan 31, 2026

symbol__ Stock Quote Price and Forecast - CNN

Jan 31, 2026